Amgen Gets Breakthrough Therapy Designation for Advanced Gastric Cancer Treatment
April 19 2021 - 4:52PM
Dow Jones News
By Kimberly Chin
Amgen Inc. has received a breakthrough therapy designation by
the U.S. Food and Drug Administration for a treatment that helps
patients with advanced gastric or gastroesophageal cancer.
The drug, bemarituzumab, has shown clinically meaningful
outcomes in patients with this kind of cancer, the company said.
The designation, which helps expedite the development and
regulatory review of medicines, paves the way for the drug to be
used as a first-line treatment in combination with modified
fluoropyrimidine, leucovorin and oxaliplatin, or FOLFOX6, the
company said.
Bemarituzumab is the second therapy in Amgen's oncology
portfolio to receive such designation in the past six months, Amgen
said.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
April 19, 2021 16:37 ET (20:37 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Amgen (NASDAQ:AMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024